Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2021-04-12
Target enrollment:
Participant gender:
Summary
In the currently proposed phase I/II study, the investigators aim to treat patients with
relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based
therapy with an FDA approved c-MET inhibitor, cabozantinib.